The Unified Multiple System Atrophy Rating Scale: Intrarater reliability

Abstract

The motor examination part of the UMSARS was found to have satisfactory intrarater reliability in the present cohort.

Blinking in patients with clinically probable multiple system atrophy

“…The diagnosis of clinically probable MSA was based on the presence of a progressive syndrome characterized by poorly levodopa‐responsive parkinsonism or cerebellar ataxia and autonomic failure . Clinical assessment included the Unified Multiple System Atrophy Rating Scale (UMSARS) part II, Mini–Mental State Examination (MMSE), and Hamilton Depression (HAM‐D) Rating Scale . Patients with severe cognitive impairment (MMSE score ≤24/30), depression (HAM‐D Rating Scale score ≥16/66) or other major psychiatric disturbances, as well as facial dyskinesias, were excluded.…”

Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting

“…Improvements in clinical measures were also identified as a research area that requires special attention. The Clinical Outcome Measures Working Group agreed that the development of a valid international rating scale based on the revision and improvement of the existing Unified MSA Rating Scale 24,25 should be the top research priority, which could be [26][27][28] There was consensus that an international registry providing standardized and comprehensive phenotypic data linked to local biobanks/biomaterial collections as well as imaging data would advance the field. Thus, the clinical outcome measure working group defined the creation of a unified dataset for MSA and implementation of an international global registry as their second top research priority.…”

Minimally clinically important decline in the parkinsonian variant of multiple system atrophy

“…Although there are likely multiple reasons for the lack of efficacy seen in clinical trials (eg, relatively short trial durations, typically small sample sizes, not targeting relevant therapeutic pathways, or failure to address early enough stages of the disease), selecting appropriate and sensitive outcome measures is of critical importance when designing new trials. The Unified Multiple System Atrophy Rating Scale (UMSARS) has been shown to be a reasonably short, multidimensional, reliable, and valid scale for the semiquantitative assessment of MSA patients, with high internal consistency and substantial‐to‐excellent interrater and intrarater agreement . Although sensitivity to change has been demonstrated, the minimally clinically important difference (MCID) has not yet been established.…”

“…The Unified Multiple System Atrophy Rating Scale (UMSARS) has been shown to be a reasonably short, multidimensional, reliable, and valid scale for the semiquantitative assessment of MSA patients, with high internal consistency and substantialto-excellent interrater and intrarater agreement. 8,9 Although sensitivity to change has been demonstrated, 10,11 the minimally clinically important difference (MCID) has not yet been established.…”